Arch Therapeutics Financials
| ARTH Stock | USD 0.21 0.01 4.55% |
With this module, you can analyze Arch financials for your investing period. You should be able to track the changes in Arch Therapeutics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Arch |
Understanding current and past Arch Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Arch Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Arch Therapeutics' assets may result in an increase in income on the income statement.
The data published in Arch Therapeutics' official financial statements typically reflect Arch Therapeutics' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Arch Therapeutics' quantitative information. For example, before you start analyzing numbers published by Arch accountants, it's essential to understand Arch Therapeutics' liquidity, profitability, and earnings quality within the context of the Health Care Equipment & Supplies space in which it operates.
Arch Therapeutics Stock Summary
Arch Therapeutics competes with Antibe Therapeutics, and Cellectis. Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company was founded in 2006 and is based in Framingham, Massachusetts. Arch Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.| Instrument | USA OTC Stock View All |
| Exchange | OTCQB Exchange |
| ISIN | US03939W1099 |
| Business Address | 235 Walnut Street, |
| Sector | Health Care Equipment & Supplies |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.archtherapeutics.com |
| Phone | 617 431 2313 |
| Currency | USD - US Dollar |
Arch Therapeutics Key Financial Ratios
Arch Therapeutics' financial ratios allow both analysts and investors to convert raw data from Arch Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Arch Therapeutics over time and compare it to other companies across industries.| Return On Equity | -40.15 | |||
| Return On Asset | -1.14 | |||
| Target Price | 3.0 | |||
| Beta | 0.72 |
Arch Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Arch Therapeutics's current stock value. Our valuation model uses many indicators to compare Arch Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arch Therapeutics competition to find correlations between indicators driving Arch Therapeutics's intrinsic value. More Info.Arch Therapeutics is rated second in return on equity category among its peers. It is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Arch Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Arch Therapeutics' OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Arch Therapeutics Systematic Risk
Arch Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Arch Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Arch Therapeutics correlated with the market. If Beta is less than 0 Arch Therapeutics generally moves in the opposite direction as compared to the market. If Arch Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Arch Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Arch Therapeutics is generally in the same direction as the market. If Beta > 1 Arch Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Arch Therapeutics January 24, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Arch Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Arch Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Arch Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Arch OTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Arch Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 16.05 | |||
| Information Ratio | 0.0447 | |||
| Maximum Drawdown | 78.57 | |||
| Value At Risk | (23.53) | |||
| Potential Upside | 25.0 |
Complementary Tools for Arch OTC Stock analysis
When running Arch Therapeutics' price analysis, check to measure Arch Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Therapeutics is operating at the current time. Most of Arch Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arch Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Therapeutics' price. Additionally, you may evaluate how the addition of Arch Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |